Fudan University

The First Chinese Home-Use Beauty Device Brand FLOSSOM Debuts at the World Congress of Dermatology

Retrieved on: 
Thursday, July 6, 2023
Research, Congress, LED, Mask, Laboratory, Algorithm, Fudan University, AI, Medical device, Dermatology, WCD

This conference was the first time in the 130-year history of the WCD that a home-use beauty device category has appeared.

Key Points: 
  • This conference was the first time in the 130-year history of the WCD that a home-use beauty device category has appeared.
  • As the first Chinese home-use beauty device brand to stand on the stage of the largest international dermatology academic event, FLOSSOM showcased the latest scientific research and medical research achievements in precision skincare to the world, representing a huge step taken by the Chinese home-use beauty device brand from China to the world.
  • Therefore, FLOSSOM hopes to bring consumers a professional skincare experience similar to that of a 'private doctor' through the application of AI technology."
  • FLOSSOM has built brand barriers through independent research and development, self built factories and 5 major laboratories, and established expert committees.

Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Retrieved on: 
Friday, June 30, 2023
Biologics license application, National Healthcare Security Administration, Partnership, Immunoglobulin G, GMG, Myasthenia gravis, Quality of life, Department of Neurology, Xuanwu hospital, Working Group, Euronext, National Healthcare, Patient, MG, Physician, Fudan University, National Medical Products Administration, Acetylcholine receptor, Neonatal Fc receptor, BLA, NMPA, NRDL, Autoimmunity, Safety, Disease, Pharmaceutical industry, Neurology

SHANGHAI, China and CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for VYVGART® (efgartigimod alfa injection), a first-in-class neonatal Fc receptor (FcRn) antagonist, as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. Zai Lab will now work with the National Healthcare Security Administration (NHSA) for NRDL inclusion to enable broad access for patients.

Key Points: 
  • Zai Lab will now work with the National Healthcare Security Administration (NHSA) for NRDL inclusion to enable broad access for patients.
  • “We are pleased to have the NMPA’s approval for VYVGART for intravenous use.
  • “We appreciate the NMPA for their thorough assessment of VYVGART, recognizing its differentiated profile and the large unmet medical need in China.
  • “We celebrate this achievement with our partner, Zai Lab, who shares our mutual passion to bring needed innovation to people with gMG in China.

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Retrieved on: 
Friday, June 30, 2023
Biologics license application, National Healthcare Security Administration, Partnership, Immunoglobulin G, GMG, Myasthenia gravis, Quality of life, Department of Neurology, Xuanwu hospital, Working Group, Euronext, National Healthcare, Patient, MG, Physician, Fudan University, National Medical Products Administration, Acetylcholine receptor, Neonatal Fc receptor, BLA, NMPA, NRDL, Safety, Disease, Pharmaceutical industry, Neurology

Amsterdam, the Netherlands— June 30, 2023 -- argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for VYVGART® (efgartigimod alfa injection), a first-in-class neonatal Fc receptor (FcRn) antagonist, as an add on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. Zai Lab will now work with the National Healthcare Security Administration (NHSA) for NRDL inclusion to enable broad access for patients.

Key Points: 
  • Zai Lab will now work with the National Healthcare Security Administration (NHSA) for NRDL inclusion to enable broad access for patients.
  • ​​​“This approval by the NMPA for VYVGART, our sixth approval globally, is the first-and-only FcRn blocker available for people living with gMG in China.
  • “We celebrate this achievement with our partner, Zai Lab, who shares our mutual passion to bring needed innovation to people with gMG in China.
  • “We appreciate the NMPA for their thorough assessment of VYVGART, recognizing its differentiated profile and the large unmet medical need in China.

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

Retrieved on: 
Thursday, June 29, 2023
Biologics license application, Therapy, Harbor, GMG, Clinical trial, Immunology, MD, Patient, National Medical Products Administration, Huashan Hospital, Fudan University, BioMed Central, Neurology, BLA, III, NMPA, Generic drug, Pharmaceutical industry

This is the first BLA accepted by NMPA since Harbour BioMed's establishment.

Key Points: 
  • This is the first BLA accepted by NMPA since Harbour BioMed's establishment.
  • "Anti-FcRn treatment is at the center of focus in gMG disease area.
  • Batoclimab is the first anti-FcRn treatment completed clinical development with positive results and confirmed efficacious and safe in Chinese gMG population.
  • "We are delighted that batoclimab has become our first BLA successfully accepted by the NMPA demonstrating our strong R&D capability.

Smart Share Global Limited Announces First Quarter 2023 Results

Retrieved on: 
Tuesday, June 20, 2023
Columbia University, Maintenance, Advertising, International Finance Corporation, Marketing, China International Capital Corporation, Kas, MBA, Fruit, CDH, US, World Bank Group, POI, Investment, Fudan University, Webcast, Reye syndrome, Depreciation, Growth, Research, Ali Baba, NYSE, Cryptocurrency, Reinsurance, Video game, Drug, Management, Internet service provider

SHANGHAI, China, June 20, 2023 (GLOBE NEWSWIRE) -- Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced its unaudited financial results for the quarter ended March 31, 2023.

Key Points: 
  • SHANGHAI, China, June 20, 2023 (GLOBE NEWSWIRE) -- Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced its unaudited financial results for the quarter ended March 31, 2023.
  • As of March 31, 2023, cumulative registered users reached 347.2 million, with 13.5 million newly registered users acquired during the quarter.
  • “During the quarter, we remain committed to expanding our coverage and improving efficiency to drive growth and achieve our strategic goals.
  • The company will hold a conference call at 8:00 A.M. Eastern Time on Tuesday, June 20, 2023 (8:00 P.M. Beijing Time on Tuesday, June 20, 2023) to discuss the financial results.

Xue Mo: Be A Messenger of LOVE and WISDOM

Retrieved on: 
Monday, June 19, 2023
Ningbo University, Faculty, Foreign language, Communication, Chinese Literature Translation Archive, Speech, University, Dean, Research, Nightmare, LOVE, Orientation, Translation, Literature, Frankfurt Book Fair, Essence, Love, Peking University, Fudan University, Mao Dun Literature Prize, Management, Entertainment

In his speech, Xue Mo emphasized the importance of love and wisdom as master keys to unlocking the world.

Key Points: 
  • In his speech, Xue Mo emphasized the importance of love and wisdom as master keys to unlocking the world.
  • In his speech, Xue Mo pointed out,
    In the wake of the pandemic, the global situation remains highly uncertain.
  • In this case, Chinese concepts of LOVE and WISDOM can precisely offer new insight into addressing the shared challenges facing humanity today.
  • So far, Xue Mo has published 105 literary and culture-themed works, some of which have been translated into more than 30 languages.

EQS-News: PUMA SE: PUMA appoints Shirley Li as General Manager China

Retrieved on: 
Monday, June 19, 2023
Football, PUMA, Marketing, Culture, Commercial director, Athlete, Fudan University, Cobra Golf, Greater China, News, Adidas, Security (finance), Management, Film industry, Sport, Golf, Running, Basketball, Motorsport

Herzogenaurach, Germany, 19 June, 2023 - Sports company PUMA has appointed Shirley Li as its new General Manager in China as part of the company’s strategy to strengthen its business in this important market.

Key Points: 
  • Herzogenaurach, Germany, 19 June, 2023 - Sports company PUMA has appointed Shirley Li as its new General Manager in China as part of the company’s strategy to strengthen its business in this important market.
  • She replaces Philippe Bocquillon, who will move into the role of PUMA’s Area Manager for Greater China, which includes China, Taiwan and Hong Kong.
  • Philippe will also take on the position of General Manager Hong Kong, while Paul Yu will remain General Manager of Taiwan.
  • I want to thank Philippe for more than 10 years as General Manager of PUMA China.

PUMA Appoints Shirley Li as General Manager China

Retrieved on: 
Monday, June 19, 2023
Other Sports, Retail, Sports, Fashion, Football, PUMA, Marketing, Culture, Multimedia, Commercial director, Athlete, Fudan University, Cobra Golf, Greater China, Adidas, Management, Film industry, Golf, Running, Basketball, Motorsport

Sports company PUMA has appointed Shirley Li as its new General Manager in China as part of the company’s strategy to strengthen its business in this important market.

Key Points: 
  • Sports company PUMA has appointed Shirley Li as its new General Manager in China as part of the company’s strategy to strengthen its business in this important market.
  • View the full release here: https://www.businesswire.com/news/home/20230619493813/en/
    Sports company PUMA has appointed Shirley Li as its new General Manager in China as part of the company’s strategy to strengthen its business in this important market.
  • Philippe will also take on the position of General Manager Hong Kong, while Paul Yu will remain General Manager of Taiwan.
  • I want to thank Philippe for more than 10 years as General Manager of PUMA China.

Global Times: Scholars call for interdisciplinary collaboration for research into origins of Chinese civilization

Retrieved on: 
Monday, June 12, 2023
Intelligence, Faculty, Science, Database, Blockchain, FISU World University Games, Probability, Dunhuang Research Academy, Survival, Sichuan University, Ageing, Social science, Chinese Academy of Sciences, Research, National Cultural Heritage Administration, Carbon, Vityaz-D Autonomous Underwater Vehicle, Proteomics, Real-time, Natural heritage, Computing, Global Times, Zhou dynasty, Museology, Archaeological science, Central China, Hunan Museum, Explorer AUV, Fudan University, Archaeology, Altitude, Digital, Longevity, Environment, Artifact, Calculus, Tea, Tourism, Pottery, Cryptocurrency, Engineering, Sanxingdui

Su Bomin, director of the Dunhuang Research Institute, said microbial infections, salt damage, and aging of applied protective materials are threatening the conservation of tomb murals.

Key Points: 
  • Su Bomin, director of the Dunhuang Research Institute, said microbial infections, salt damage, and aging of applied protective materials are threatening the conservation of tomb murals.
  • "Protein evidence extracted from dental calculus indicates that the consumption of dairy products was an important cultural adaptation," Lü said.
  • The scholars have high esteem for their campaigns, as they believe what they are doing is not a one-time effort.
  • Even if we do not receive funding, we will still need to pursue research."

ADHD: inattention and hyperactivity have been the focus of research – but emotional problems may be the missing link

Retrieved on: 
Saturday, June 10, 2023
Dopamine, Learning, Technology, Depression, University, IPad, Nature Medicine, DSM-IV codes, Prevalence, Attention deficit hyperactivity disorder predominantly inattentive, Impulsivity, Solution, Parent, Anxiety, Neuroimaging, Reward, Prefrontal cortex, Prescription, Brain, Emotion, Attention, Research, Decoder, Methylphenidate, Attention deficit hyperactivity disorder, Emotional dysregulation, Anxiety disorder, Cognitive development, Self-control, National Health, Mood disorder, Sibling, Time, Serotonin, Striatum, NP, National Health Interview Survey, Fudan University, Deficit spending, Motivation, Diagnosis, Ageing, DSM-5, Function (mathematics), Mental health, Dietary supplement, Toy, Medical imaging, Nursing, ADHD

ADHD is diagnosed using criteria from a document called DSM-5, which include symptoms of inattention, hyperactivity and impulsivity.

Key Points: 
  • ADHD is diagnosed using criteria from a document called DSM-5, which include symptoms of inattention, hyperactivity and impulsivity.
  • But it is becoming increasingly clear to researchers that the condition also comes with self-control problems, affecting the ability to regulate emotions.
  • For example, 2.1% of children with a diagnosis of ADHD also have a mood disorder, such as depression, while 27.4% have an anxiety disorder.
  • Children with anxiety and depression symptoms only exhibited those deficits if they also had problems with attention.
  • So it seems that one possible route to helping children with ADHD or mood disorders with cognitive development is to focus on improving their attention.

Treatments

    • Methylphenidate roughly works by increasing three chemicals in the brain: dopamine, serotonin and noradrenaline.
    • Dopamine can improve attention, learning, working memory and motivation, while noradrenaline reduces impulsivity and boosts attention.
    • This research suggests that cognitive control, which is associated with frontal areas, can be improved by methylphenidate.
    • This should be offered to children with ADHD, in conjunction with pharmacological treatments.

ADHD on the rise

    • The number of ADHD diagnoses are rising across the world, and so are prescriptions of methylphenidate.
    • In the UK, a study estimated that the use of ADHD medications has increased by almost 800% from 2000 to 2015.
    • It may be that the prevalence of ADHD will increase even more in the future as coping strategies become less effective and people seek help and ultimately receive a diagnosis.
    • The more we learn about brain basis of ADHD, the easier it will get to treat.